Patient-derived Organoids of Lung Cancer to Test Drug Response

NCT ID: NCT03979170

Last Updated: 2024-06-03

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-04-01
• Study Completion Date: 2029-12-30

Brief Summary

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.

Detailed Description

The aim of the project is to use a combination of patient-derived organoid models:

• To amplify tumour tissue to obtain enough material for genomic and histological analysis
• to characterize the lung cancer sub-type
• To predict treatment (non)response.

The following points will be addressed:

1. First, the investigators plan to establish and characterize formation of organoids from biopsies of patients with lung cancer: in spheroids, in the 3D cellular model OncoCilAirTM (OncoTheis), and on the chick chorioallantoic membrane (CAM). Patient-derived organoids from tumoural tissue (PDO) will be characterized and compared to the original tumour.

2. Second, the investigators will test the chemoresponse (chemosensitivity and chemoresistance) of organoids to anti-cancer treatment.

Conditions

Lung Cancer; Organoid

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Lung tumor resection

lung tumor resection

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Histologically proven lung cancer
• Age ≥ 18
• Written informed and signed consent
• Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour

Exclusion Criteria

• Less than 18 years of age
• Not able to give informed consent (language, intellectual capacities, etc.)
• Not accessible to biopsy and/or surgery sample
• Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Frederic TRIPONEZ

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Geneva University Hospitals

Geneva, , Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Veronique SERRE-BEINIER, PhD

Role: CONTACT

veronique.serre-beinier@hcuge.ch

(0)223795107 ext. +41

Facility Contacts

Veronique SERRE-BEINIER, PhD

Role: primary

veronique.serre-beinier@hcuge.ch

223795107 ext. 41

References

Mueggler A, Pilotto E, Perriraz-Mayer N, Jiang S, Addeo A, Bedat B, Karenovics W, Triponez F, Serre-Beinier V. An Optimized Method to Culture Human Primary Lung Tumor Cell Spheroids. Cancers (Basel). 2023 Nov 25;15(23):5576. doi: 10.3390/cancers15235576.

Reference Type: BACKGROUND

PMID: 38067281 (View on PubMed)

Other Identifiers

2018-02395

Identifier Type: -

Identifier Source: org_study_id